Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda, PRA to Launch JV in Japan to Take Over 140 Employees
Takeda Pharmaceutical and US CRO PRA Health Sciences will establish a joint venture in Japan, which will take over around 140 employees and some functions from the Japanese giant’s drug development division, the two companies said on February 15. The…
To read the full story
Related Article
- Dissolving JV with Takeda, PRA Launches Independent CRO Biz in Japan
July 24, 2019
- Takeda-PRA Joint Venture in Japan to Be Formed on June 1
April 10, 2017
- As Takeda’s R&D Rejig Progresses, Biotech JV Launch Sets Direction for Its Japan Regime
March 23, 2017
- Takeda, PRA Health Ink Broad Partnership in US, Europe; 300 Development Staffers Given Option to Transfer
September 14, 2016
BUSINESS
- Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
- Women Hold Nearly 1/4 of Leadership Roles at Japan’s Listed Pharmas and Wholesalers
July 10, 2026
- Expert Welcomes Talvey-Tecvayli Combo for Difficult-to-Treat MM
July 10, 2026
- Axcelead Teams Up with Mitsubishi to Expand Drug Discovery Support Biz
July 10, 2026
- Roche PD-L1 Test Approved for Imfinzi in Endometrial Cancer
July 10, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…